CN116710114B9 - Glp-1/glp-2双重激动剂的药物组合物 - Google Patents

Glp-1/glp-2双重激动剂的药物组合物

Info

Publication number
CN116710114B9
CN116710114B9 CN202180080845.4A CN202180080845A CN116710114B9 CN 116710114 B9 CN116710114 B9 CN 116710114B9 CN 202180080845 A CN202180080845 A CN 202180080845A CN 116710114 B9 CN116710114 B9 CN 116710114B9
Authority
CN
China
Prior art keywords
glp
composition
aspects
concentration
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180080845.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN116710114B (zh
CN116710114A (zh
Inventor
杰斯珀·斯科博格·维拉德森
利塞·吉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zealand Pharma AS
Original Assignee
Zealand Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma AS filed Critical Zealand Pharma AS
Publication of CN116710114A publication Critical patent/CN116710114A/zh
Publication of CN116710114B publication Critical patent/CN116710114B/zh
Application granted granted Critical
Publication of CN116710114B9 publication Critical patent/CN116710114B9/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202180080845.4A 2020-12-16 2021-12-16 Glp-1/glp-2双重激动剂的药物组合物 Active CN116710114B9 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20214562 2020-12-16
EP20214562.9 2020-12-16
PCT/EP2021/086147 WO2022129311A1 (en) 2020-12-16 2021-12-16 Pharmaceutical composition of glp-1/glp-2 dual agonists

Publications (3)

Publication Number Publication Date
CN116710114A CN116710114A (zh) 2023-09-05
CN116710114B CN116710114B (zh) 2025-11-25
CN116710114B9 true CN116710114B9 (zh) 2026-01-02

Family

ID=74141274

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180080845.4A Active CN116710114B9 (zh) 2020-12-16 2021-12-16 Glp-1/glp-2双重激动剂的药物组合物

Country Status (13)

Country Link
US (1) US20240024425A1 (https=)
EP (1) EP4262745B1 (https=)
JP (1) JP7809117B2 (https=)
KR (1) KR20230121823A (https=)
CN (1) CN116710114B9 (https=)
AU (1) AU2021404497A1 (https=)
CA (1) CA3200526A1 (https=)
CL (1) CL2023001747A1 (https=)
ES (1) ES3019509T3 (https=)
IL (1) IL301893A (https=)
MX (1) MX2023006284A (https=)
WO (1) WO2022129311A1 (https=)
ZA (1) ZA202304235B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111311WA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
IL301892A (en) * 2020-12-16 2023-06-01 Zealand Pharma As Drug composition of dual GLP-1/GLP-2 agonists
JP2024533153A (ja) * 2021-09-03 2024-09-12 ジーランド ファーマ エー／エス 投薬レジーム

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1571676A (zh) * 2001-10-19 2005-01-26 伊莱利利公司 Glp－1和胰岛素的双相混合物
CN110088125A (zh) * 2016-12-09 2019-08-02 西兰制药公司 酰化的glp-1/glp-2双重激动剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
ES2373660T3 (es) 2003-11-13 2012-02-07 Novo Nordisk A/S Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo.
CN104902922B (zh) * 2012-11-13 2017-12-12 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
AR110300A1 (es) * 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
SG11202111311WA (en) * 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1571676A (zh) * 2001-10-19 2005-01-26 伊莱利利公司 Glp－1和胰岛素的双相混合物
CN110088125A (zh) * 2016-12-09 2019-08-02 西兰制药公司 酰化的glp-1/glp-2双重激动剂

Also Published As

Publication number Publication date
JP7809117B2 (ja) 2026-01-30
ES3019509T3 (en) 2025-05-20
IL301893A (en) 2023-06-01
CN116710114B (zh) 2025-11-25
CL2023001747A1 (es) 2024-01-19
CA3200526A1 (en) 2022-06-23
MX2023006284A (es) 2023-06-13
US20240024425A1 (en) 2024-01-25
EP4262745C0 (en) 2025-01-29
ZA202304235B (en) 2025-08-27
JP2023553561A (ja) 2023-12-22
KR20230121823A (ko) 2023-08-21
TW202228764A (zh) 2022-08-01
WO2022129311A1 (en) 2022-06-23
EP4262745B1 (en) 2025-01-29
AU2021404497A1 (en) 2023-06-08
CN116710114A (zh) 2023-09-05
EP4262745A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
CN113966226B (zh) 双重glp1/2激动剂的药物肠胃外组合物
CN116710114B9 (zh) Glp-1/glp-2双重激动剂的药物组合物
CN116669752B (zh) Glp-1/glp-2双重激动剂的药物组合物
AU2021401137B2 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
TWI921427B (zh) Glp-1/glp-2雙重促效劑之醫藥組合物
RU2855506C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
RU2852511C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
RU2855486C1 (ru) Фармацевтическая композиция двойных агонистов glp-1/glp-2
HK40095698B (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
HK40095698A (en) Pharmaceutical composition of glp-1/glp-2 dual agonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CI03 Correction of invention patent

Correction item: Claims

Correct: Correct

False: Error

Number: 48-01

Page: full text

Volume: 41

CI03 Correction of invention patent